Market capitalization | $2.73m |
Enterprise Value | $48.23m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 96.46 |
P/S ratio (TTM) P/S ratio | 5.46 |
P/B ratio (TTM) P/B ratio | 0.12 |
Revenue growth (TTM) Revenue growth | -81.66% |
Revenue (TTM) Revenue | $500.00k |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
3 Analysts have issued a Gritstone Oncology, Inc. forecast:
3 Analysts have issued a Gritstone Oncology, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 0.50 0.50 |
82%
82%
|
|
Gross Profit | -6.73 -6.73 |
57%
57%
|
|
EBITDA | -143 -143 |
17%
17%
|
EBIT (Operating Income) EBIT | -151 -151 |
7%
7%
|
Net Profit | -133 -133 |
2%
2%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Gritstone Oncology, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria in August 2015 and is headquartered in Emeryville, CA.
Head office | United States |
CEO | Andrew Allen |
Employees | 231 |
Founded | 2015 |
Website | www.gritstonebio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.